BR112013031201A2 - heterocyclic sulfonamide derivatives, pharmaceutical composition comprising them, use, process for the manufacture of (r) -n- (4,5-difluoro-6 - ((2-fluoro-4-iodophenyl) amino) benzofuran-7-yl) -1- (2,3-dihydroxypropyl) cyclopropane-5-1-sulfonamide and kit - Google Patents

heterocyclic sulfonamide derivatives, pharmaceutical composition comprising them, use, process for the manufacture of (r) -n- (4,5-difluoro-6 - ((2-fluoro-4-iodophenyl) amino) benzofuran-7-yl) -1- (2,3-dihydroxypropyl) cyclopropane-5-1-sulfonamide and kit

Info

Publication number
BR112013031201A2
BR112013031201A2 BR112013031201A BR112013031201A BR112013031201A2 BR 112013031201 A2 BR112013031201 A2 BR 112013031201A2 BR 112013031201 A BR112013031201 A BR 112013031201A BR 112013031201 A BR112013031201 A BR 112013031201A BR 112013031201 A2 BR112013031201 A2 BR 112013031201A2
Authority
BR
Brazil
Prior art keywords
sulfonamide
iodophenyl
dihydroxypropyl
cyclopropane
benzofuran
Prior art date
Application number
BR112013031201A
Other languages
Portuguese (pt)
Inventor
Wang Can
Poddutoori Ramulu
Zhao Xianglin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013031201A2 publication Critical patent/BR112013031201A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

resumo patente de invenção: "derivados de sulfonamida heterocíclicos". a presente invenção refere-se a compostos: (i) e seus sais farmaceuticamente aceitáveis. os compostos foram demonstrados como inibidores de mek e, portanto, podem ser úteis no tratamento de doenças hiperproliferativas como câncer e inflamação.patent summary: "heterocyclic sulfonamide derivatives". The present invention relates to compounds: (i) and pharmaceutically acceptable salts thereof. The compounds have been shown to inhibit mek and therefore may be useful in treating hyperproliferative diseases such as cancer and inflammation.

BR112013031201A 2011-06-09 2012-06-06 heterocyclic sulfonamide derivatives, pharmaceutical composition comprising them, use, process for the manufacture of (r) -n- (4,5-difluoro-6 - ((2-fluoro-4-iodophenyl) amino) benzofuran-7-yl) -1- (2,3-dihydroxypropyl) cyclopropane-5-1-sulfonamide and kit BR112013031201A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1634DE2011 2011-06-09
CN201210175145 2012-05-31
PCT/IB2012/052860 WO2012168884A1 (en) 2011-06-09 2012-06-06 Heterocyclic sulfonamide derivatives

Publications (1)

Publication Number Publication Date
BR112013031201A2 true BR112013031201A2 (en) 2017-01-31

Family

ID=46384435

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031201A BR112013031201A2 (en) 2011-06-09 2012-06-06 heterocyclic sulfonamide derivatives, pharmaceutical composition comprising them, use, process for the manufacture of (r) -n- (4,5-difluoro-6 - ((2-fluoro-4-iodophenyl) amino) benzofuran-7-yl) -1- (2,3-dihydroxypropyl) cyclopropane-5-1-sulfonamide and kit

Country Status (10)

Country Link
EP (1) EP2718276A1 (en)
JP (1) JP2014517004A (en)
KR (1) KR20140034898A (en)
AU (1) AU2012265844A1 (en)
BR (1) BR112013031201A2 (en)
CA (1) CA2838029A1 (en)
EA (1) EA201391820A1 (en)
IN (1) IN2014DN00123A (en)
MX (1) MX2013014398A (en)
WO (1) WO2012168884A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104011039A (en) * 2011-12-19 2014-08-27 住友化学株式会社 Method for producing sulfonate
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN104886052B (en) * 2015-06-02 2016-08-31 吉林省八达农药有限公司 A kind of application of cyclopropyl-sulfonylamide
US10736897B2 (en) * 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
WO2019183385A1 (en) * 2018-03-22 2019-09-26 University Of Rochester Mapk/erk inhibition for ovarian and other cancers

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (en) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide and its pharmaceutically acceptable salts and esters (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (en) 1992-04-03 1994-06-21 Ciba Geigy Ag
ES2278663T3 (en) 1992-10-28 2007-08-16 Genentech, Inc. ANTAGONISTS OF THE VEGF VASCULAR ENDOTELIAL CELLS GROWTH FACTOR.
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ES2332984T3 (en) 1995-03-30 2010-02-16 Pfizer Products Inc. DERIVATIVES OF QUINAZOLINAS.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DK0836605T3 (en) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidines and Methods for their Preparation
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
ATE308527T1 (en) 1996-06-24 2005-11-15 Pfizer PHENYLAMINO-SUBSTITUTED TRIICYCLIC DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
EP0938597B1 (en) 1996-09-06 2003-08-20 Obducat Aktiebolag Method for anisotropic etching of structures in conducting materials
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
WO1998022461A1 (en) 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (en) 1997-02-13 2000-09-01 Novartis Ag PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
ES2342240T3 (en) 1998-08-11 2010-07-02 Novartis Ag ISOQUINOLINE DERIVATIVES WITH ACTIVITY INHIBITED BY ANGIOGENIA.
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
IL143069A0 (en) 1998-11-20 2002-04-21 Kosan Biosciences Inc Recombinant methods and materials for producing epothilone and epothilone derivatives
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
WO2000059509A1 (en) 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
AR035885A1 (en) 2001-05-14 2004-07-21 Novartis Ag DERIVATIVES OF 4-AMINO-5-FENIL-7-CYCLLOBUTILPIRROLO (2,3-D) PYRIMIDINE, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2006083137A (en) * 2004-09-17 2006-03-30 Sankyo Co Ltd Immunosuppressive agent
WO2008089459A1 (en) * 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of mek
CA2924436A1 (en) * 2007-07-30 2009-02-05 Ardea Biosciences, Inc. Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use
CA2717529A1 (en) * 2008-03-11 2009-09-17 Cellzome Limited Sulfonamides as zap-70 inhibitors
CN102137847B (en) * 2008-07-01 2015-06-10 健泰科生物技术公司 Bicyclic heterocycles as MEK kinase inhibitors
CA2761108A1 (en) * 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
CN102134218A (en) * 2009-06-15 2011-07-27 凯美隆(北京)药业技术有限公司 6-aryl amino pyridone sulfamide and 6-aryl amino pymetrozine sulfamide methyl ethyl ketone (MEK) inihibitor
AU2010317167B2 (en) * 2009-11-04 2012-11-29 Novartis Ag Heterocyclic sulfonamide derivatives useful as MEK inhibitors
GEP20135998B (en) * 2009-12-08 2013-12-25 Novartis Ag Heterocyclic sulfonamide derivatives

Also Published As

Publication number Publication date
AU2012265844A1 (en) 2013-05-02
JP2014517004A (en) 2014-07-17
WO2012168884A1 (en) 2012-12-13
EP2718276A1 (en) 2014-04-16
KR20140034898A (en) 2014-03-20
CA2838029A1 (en) 2012-12-13
EA201391820A1 (en) 2014-12-30
IN2014DN00123A (en) 2015-05-22
MX2013014398A (en) 2014-03-21

Similar Documents

Publication Publication Date Title
BR112013000920A2 (en) compounds for reducing beta-amyloid production
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
BR112015017997A8 (en) quinoline and quinoxaline amides as sodium channel modulators, pharmaceutical compositions comprising them and use
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
EA201490774A1 (en) NEW OXAZINE DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
BR112013021537A2 (en) thiazolylpenylbenzenesulfonamide derivatives as kinase inhibitors
EA201591363A1 (en) TIADIAZOLE ANALOGUES AND METHODS OF TREATMENT OF STATES ASSOCIATED WITH SMN DEFICIENCY
BR112014015363A2 (en) alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
BR112016000825A8 (en) sodium channel sulfonamide modulating compounds, pharmaceutical composition, and use thereof
EA201592255A1 (en) DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
BR112018068565A2 (en) lsd1 inhibitor combinations for use in treating solid tumors
EA201491671A1 (en) Heterocyclic Compounds
EA201390626A1 (en) DERIVATIVES OF HYDROXAMIC ACID AND APPLICATION OF INDICATED DERIVATIVES IN THE TREATMENT OF BACTERIAL INFECTIONS
EA201592254A1 (en) DERIVATIVES OF Pyrazolopyrrolidin-4-IT and THEIR APPLICATION IN THE TREATMENT OF DISEASE
BR112014005389A8 (en) 4-(3-METANOSULFONYL-PHENYL)-1- PROPYL-PIPERIDINE CHLORIDE SALT IN A CRYSTALLINE FORM, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USES OF SAID SALT
EA201391486A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE
BR112014017780A8 (en) TRICYCLIC SULPHONE COMPOUNDS AND METHODS FOR MAKING AND USING THEM
EA201101533A1 (en) HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS
BR112013031201A2 (en) heterocyclic sulfonamide derivatives, pharmaceutical composition comprising them, use, process for the manufacture of (r) -n- (4,5-difluoro-6 - ((2-fluoro-4-iodophenyl) amino) benzofuran-7-yl) -1- (2,3-dihydroxypropyl) cyclopropane-5-1-sulfonamide and kit
BR112013000248A2 (en) spirocyclically substituted 1,3-propane dioxide derivatives, method for their production and use as a medicament
BR112013029999A2 (en) thiazole derivatives
BR112014031091A2 (en) PIPERIDINE DERIVATIVES FOR GPR119 AGONIST
BR112013019160A2 (en) new compounds, pharmaceutical composition, use, processes and methods

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]